NCT02560883 Hairy Cell Leukemia Patient Data Registry
| NCT ID | NCT02560883 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ohio State University Comprehensive Cancer Center |
| Condition | Leukemia, Other |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2013-01-02 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2013-01-02 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall objective is to develop a clinical data registry that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality and improving the quality of life of patients diagnosed or living with hairy cell leukemia. With approximately 1,000 new cases of this rare disease identified in the US each year, HCL represents 2% of all cases of leukemia in adults. Considering the rarity of this chronic leukemia, the Hairy Cell Leukemia Foundation (HCLF), in partnership with investigators from its Centers of Excellence, seeks to develop a registry to help researchers identify new trends in outcomes, recognize the most effective treatments, discover previously unknown complications of the disease, and design clinical trials for new therapies.
Eligibility Criteria
Inclusion: * Patients with classic hairy cell leukemia * Patients with the variant of hairy cell leukemia. Exclusion: * Children are excluded from the study, since Hairy Cell Leukemia wasn't described in children.
Contact & Investigator
Michael Grever, MD
PRINCIPAL INVESTIGATOR
The Ohio State University Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT02560883 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Leukemia, Other. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02560883 currently recruiting?
Yes, NCT02560883 is actively recruiting participants. Contact the research team at HCLRegistry@osumc.edu for enrollment information.
Where is the NCT02560883 trial being conducted?
This trial is being conducted at Miami, United States, Miami Beach, United States, Rochester, United States, Rochester, United States and 4 additional locations.
Who is sponsoring the NCT02560883 clinical trial?
NCT02560883 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Michael Grever, MD at The Ohio State University Comprehensive Cancer Center. The trial plans to enroll 5,000 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.